about
Sin3b interacts with Myc and decreases Myc levelsCyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinomaCorrelation of Snail expression with histological grade and lymph node status in breast carcinomasClinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifenMelanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METFunctional characterization of E- and P-cadherin in invasive breast cancer cells.Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives.The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells.Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma.Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomasLOXL2 in epithelial cell plasticity and tumor progression.Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancerE47 and Id1 interplay in epithelial-mesenchymal transitionSNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells.KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.MicroRNA-dependent regulation of transcription in non-small cell lung cancer.Gasdermin-B promotes invasion and metastasis in breast cancer cells.Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression.Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors.Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progressionVimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomasHigh frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination.Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.Telling cells how to die: docetaxel therapy in cancer cell lines.PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.Cancer network activity associated with therapeutic response and synergism.Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.Transcriptional regulation of cell polarity in EMT and cancer."New" molecular taxonomy in breast cancer.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancerThe truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.Endometrial carcinoma: molecular alterations involved in tumor development and progression.The EMT signaling pathways in endometrial carcinoma.MicroRNAs as prognostic markers in ovarian cancer.Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
P50
Q24299671-104E7A55-C13F-4091-93E9-FCCBC87F1B66Q28188670-23A644A8-EC51-48C5-879C-6FAD0065D6F3Q28206944-9B554D3D-D556-4B02-8A4D-0566A6B306D8Q28281218-8760BE53-381F-4CD5-B40D-FFE5081284DAQ29618139-4FAF910A-FB0B-4654-99C0-88B275B111DCQ33414412-18F23FBF-4D2C-4A34-B4F9-0F740C47423DQ33559304-7FD93C5A-36B7-4008-9B63-615DC84FE7CDQ33688523-AC8D10D0-5028-45BB-A0BD-570BE0CD4FDBQ33721249-C0BC6901-6997-47F2-82B7-BB9930E6DBC1Q33988841-4E866F62-35A9-4C95-BA92-2D452ECD1BD0Q34049715-0CEA055E-840A-46F8-813A-DBE9C6CC6D81Q34153009-0B0D7749-F662-40E5-9A50-E5FDE01B8EEAQ34197948-360ADC0B-933C-4E06-BB34-3EBF04AF55ADQ34303455-15ECF7DB-1044-4142-8F97-1ED064DB3B90Q34310001-67901CA1-00D4-4687-81D0-F3400CF680D5Q34652699-F4DA738B-4089-4885-8CE9-000A5D46DA02Q34727364-E76A6A3A-91B1-486B-B60B-1BEDCB703BBBQ34805471-BCD79C7E-FC26-4071-9712-C363E990A517Q35119983-203C2750-1D32-49F5-96A0-A594CA9DD2A5Q35133195-82C54685-B8EB-4C55-8D8E-201B270C5EF4Q35527142-486C3C78-25BA-484A-B50B-CEAF7ACEC8EAQ35562695-3ADE7331-5231-4D86-A136-759A38D380E2Q35856294-9AF591E8-C493-4AC2-8E9F-99B2F3CB888AQ35984566-CDCD236F-AA85-4134-AEE9-A9E4B67A3AB1Q36375053-293B2B5F-ED65-4AD4-958C-AD5A46109B30Q36490260-AC08A438-E8E6-4FC9-920B-8056FFE3734AQ36546008-6B356947-AD60-40E5-AB33-1F36BFC7321FQ36766382-721DA43D-7F57-4F55-9957-A4434A1CF49EQ37131335-CBEB5473-4229-478A-A5C3-76E43B7FC607Q37199267-75920EFC-9FE2-4083-BAD9-12CEA66FE068Q37221493-0EE9314F-A9A2-46A1-BB99-A808F2A59446Q37293102-B801F1A6-67ED-4E2D-9236-C4E1DE86AEEFQ37333606-6A80D8DD-C8C4-403C-943D-B9A0DF340B1CQ37345122-CB857014-BACC-4591-9AD3-993F9A0C18D3Q37636623-CFF93620-74EE-4F77-8D0E-2ED6841A09EBQ37644995-35428E01-884B-456B-9F5A-126CCBEE80B9Q37994980-DA510C9D-0881-449D-8527-F34CDD7C1C9DQ38036605-A3DF155E-E2FC-4C5A-8BDD-B0B7018D19E2Q38205688-A3A8FDDF-FF61-444D-990A-7E0AC1BC15EAQ38321774-B9E0350E-ABDA-4AFF-B89B-39649EECFFE5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gema Moreno-Bueno
@ast
Gema Moreno-Bueno
@en
Gema Moreno-Bueno
@es
Gema Moreno-Bueno
@nl
Gema Moreno-Bueno
@sl
type
label
Gema Moreno-Bueno
@ast
Gema Moreno-Bueno
@en
Gema Moreno-Bueno
@es
Gema Moreno-Bueno
@nl
Gema Moreno-Bueno
@sl
altLabel
Moreno G
@en
Moreno-Bueno G
@en
prefLabel
Gema Moreno-Bueno
@ast
Gema Moreno-Bueno
@en
Gema Moreno-Bueno
@es
Gema Moreno-Bueno
@nl
Gema Moreno-Bueno
@sl
P1053
K-9354-2016
P106
P1153
6603405238
P21
P31
P3829
P496
0000-0002-5030-6687